EU Regulator Backs Revoking Amgen's Right to Sell Rare-Disease Drug
The European Medicines Agency recommended revoking Amgen's marketing authorization for its rare-disease drug Tavneos due to unreliable clinical trial data. This aligns with a similar FDA proposal, pro
reuters · 2026-06-26 04:10